ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer
ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer
复制标题
DOI：
10.1007/s00428-012-1270-7
复制
发表时间：
2012-07
期刊：
影响因子：
3.5
通讯作者：
V. Scheble;G. Scharf;M. Braun;C. Ruiz;Susanna Stürm;Karen Petersen;R. Beschorner;A. Bachmann;T. Zellweger;F. Fend;G. Kristiansen;L. Bubendorf;N. Wernert;Zaki Shaikhibrahim-;S. Perner
中科院分区：
文献类型：
--
作者：
V. Scheble;G. Scharf;M. Braun;C. Ruiz;Susanna Stürm;Karen Petersen;R. Beschorner;A. Bachmann;T. Zellweger;F. Fend;G. Kristiansen;L. Bubendorf;N. Wernert;Zaki Shaikhibrahim-;S. Perner
去势抵抗性前列腺癌是癌症死亡的第二大常见原因，导致中位生存期不到 2 年。在前列腺癌中，TMPRSS2 和 ERG 之间的融合很常见。与远处转移性前列腺癌相比，局部复发性去势抵抗性前列腺癌的ERG重排患病率尚不清楚。我们研究了局部复发性去势抵抗性前列腺癌与远处转移性前列腺癌相比的ERG重排频率，并评估了雄激素受体（AR）扩增与ERG重排状态之间的关联。通过荧光原位杂交评估了 134 名诊断患有前列腺癌的患者（84 名局部复发性去势抵抗性前列腺癌，55 名远处转移性前列腺癌）的样本的 EGR 重排和 A 扩增状态。采用χ2检验进行统计分析。我们发现，ERG重排在远处转移性前列腺癌中发生的频率 (25%) 明显低于局部复发性去势抵抗性前列腺癌 (45%)。局部复发性去势抵抗性前列腺癌和远处转移性前列腺癌的 AR 扩增频率分别为 45% 和 35%。与局部复发性去势抵抗性前列腺癌相比，ERG重排在远处转移性前列腺癌中发生的频率较低。
Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions betweenTMPRSS2andERGare common. TheERGrearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency ofERGrearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification andERGrearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for theirERGrearrangement andARamplification status by fluorescence in situ hybridization. Statistical analysis was performed using theχ2test. We found that theERGrearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). TheARamplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. TheERGrearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.